High basal and continuously increasing fasting insulin level is a marker for the development of non-alcoholic fatty liver diseases (NAFLD) [177], and elevated insulin would increase SREBP-1c, coordinating LXR and ChREBP to promote the expression of lipogenic genes and de novo lipogenesis in the liver [50]. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.